Immuneering Corp (IMRX NASDAQ) stock market data APIs
$4.9198
-0.31(-6.3%)
as of February 6, 2026
Try our APIs with
free plan!
Immuneering Corp Financial Data Overview
Price chart is built with
Anychart
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Prev. Close
4.9198
Open
4.6095
High
5.0151
Low
4.5575
52 wk Range
1.1-10.08
Market Cap
318 M
Shares Outstanding
64 570 K
Revenue
455
EPS
-0.38
Beta
0.459
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immuneering Corp (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immuneering Corp data using free add-ons & libraries
Get Immuneering Corp Fundamental Data
Immuneering Corp Fundamental data includes:
- Net Revenue: 455
- EBITDA: -63 817 392
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immuneering Corp News
New
IMRX Reports 12-Month Survival Of 64% In First-Line Pancreatic Cancer Patients; But Stock Plunges
(RTTNews) - Immuneering Corp. (IMRX) announced positive updated results from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line met...
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial
(RTTNews) - Immuneering Corporation (IMRX) announced that it will present updated 12-month overall survival data from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabin...
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026
(RTTNews) - Immuneering Corp. (IMRX), a late-stage clinical oncology company, announced that it is on track to dose the first patient in its planned phase 3 trial of Atebimetinib in first-line metasta...
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering Corporation NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
